Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China

Jianqiu Wu, Jifeng Feng, Liping Su et al.|Chinese Medical Journal|2018

Cited by 27